Lumasiran · OXLUMO

RNA / oligonucleotide

Approvedregulatory verdict

Evidence outlook

Approved: Primary Hyperoxaluria Type 1

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
CA
  • Primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in paediatric and adult patients (OXLUMO)
Product first approved 2022newswire.ca
EU
  • Primary hyperoxaluria type 1 (PH1) in all age groups
Product first approved 2020EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Primary Hyperoxaluria Type 1
NCT03905694 · Alnylam Pharmaceuticals
2019-04-22 – 2024-07-26 · Primary Hyperoxaluria, Primary Hyperoxaluria Type 1 (PH1)
What this study did
Phase 2 (3)
Primary Hyperoxaluria Type 1
NCT03350451 · Alnylam Pharmaceuticals
2018-04-04 – 2023-02-07 · PH1, Primary Hyperoxaluria, RNAi Therapeutic, siRNA, AGT
What this study did
Other / comorbidity
NCT06225544 · Charite University, Berlin, Germany
2024-04-14 – 2025-03-01 · Haemodialysis, Chronic Kidney Disease Requiring Chronic Dialysis, Cardiovascular Disease, Cardiovascular Risk Factor, Hyperoxalemia
What this study did
NCT05161936 · Alnylam Pharmaceuticals
2022-01-27 – 2022-11-01 · Recurrent Calcium Oxalate Kidney Stone Disease, Elevated Urinary Oxalate Levels
What this study did
Phase 1/2 (1)
Primary Hyperoxaluria Type 1
NCT02706886 · Alnylam Pharmaceuticals
2016-03-08 – 2019-01-23 · Primary Hyperoxaluria Type 1 (PH1)
What this study did

Competitive landscape

This drug's own stage for Primary Hyperoxaluria Type 1: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Lumasiran (OXLUMO): this drugApprovedRNA / oligonucleotideHAO1 (glycolate oxidase)Weak signal
NCT03681184: Percent Change in 24-hour Urinary Oxalate Excretion Corrected for Body Surface Area (BSA) From Baseline to Month 6 (Baseline to Month 6): Placebo/Lumasiran -11.8 percent change (Standard Error 3.8) | Lumasiran/Lumasiran -65.4 percent change (Standard Error 2.9)
Nedosiran (Rivfloza)ApprovedRNA / oligonucleotideLDHA (lactate dehydrogenase A) mRNAnot yet gradedNo reviewed efficacy summary in this indication
StiripentolPhase 3Small moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.